- In March 2024, Amgen announced new 52-week results from the Phase 3 SPROUT study on Otezla (apremilast) in children and adolescents (6-17 years) with moderate to severe plaque psoriasis. Additionally, Phase 3 late-breaking study results on Otezla in palmoplantar pustulosis will be presented at the 2024 AAD Annual Meeting in San Diego. These findings will enhance Amgen's market position by showcasing Otezla’s efficacy in diverse dermatological conditions, expanding its potential patient base
- In August 2023, Kyowa Kirin Co., Ltd. announced that it has received approval from the Ministry of Health, Labour and Welfare (MHLW) for a partial change in the approved indication of LUMICEF (brodalumab) to treat palmoplantar pustulosis (PPP) in patients who do not respond adequately to existing therapies. This approval will enhance the company's portfolio, offering a new treatment option for PPP patients and expanding its presence in the dermatology market.
